To include your compound in the COVID-19 Resource Center, submit it here.

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

Regulatory milestones

Allergan Inc. (NYSE:AGN) lost $0.68 to $79.14 last week after the U.K.'s NICE recommended use of Ozurdex dexamethasone intravitreal implant to treat macular edema following central retinal vein occlusion (CRVO). NICE also recommended Ozurdex for macular edema following branch retinal vein occlusion (BRVO) when laser photocoagulation is not beneficial or suitable (see Online Links, A21).

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) lost $3.46 to $54.58 last week after partner Bayer AG (Xetra:BAY) submitted an MAA to EMA for VEGF Trap-Eye to

Read the full 793 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE